Survivorship after lasting benefit from immunotherapy for advanced cancer
Official title: A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
Funded at Roswell Park Cancer Institute Corp · NIH-11168670 · Data updated 2026-11-12
This project follows people with advanced cancers who have had long-lasting benefit from immunotherapy to track their health, symptoms, and care needs over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 14, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $766,294 |
| NIH project number | 5R01CA281862-03 |
| Project ID | NIH-11168670 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with advanced lung cancer, kidney cancer, or melanoma who had a partial or complete response to an immune checkpoint inhibitor and have lived at least one year after starting that treatment.
✕Less likely to help
People who never received immune checkpoint inhibitors, who did not have a durable response, or whose cancer types are not part of the prospective cohort may not directly benefit from this project.
What this research studies
If you join, researchers will look back at medical records from about 8,860 patients treated with immune checkpoint inhibitors between 2014 and 2022 to find people who had durable responses. They will also enroll and actively follow about 1,200 people with advanced lung cancer, kidney cancer, or melanoma who have had a lasting response to these drugs. Clinical information and patient-reported surveys will be collected at enrollment and every six months to map long-term survival, physical symptoms, and psychosocial needs. The team will use these combined data to learn which factors link to lasting benefit and what supports survivors need.
Why it matters
Potential benefit: If successful, this work could help tailor follow-up care and symptom support for people who live long after immunotherapy.
How similar studies have gone: Immune checkpoint inhibitors are already known to produce durable remissions for some patients, but large multi-institutional follow-up efforts focused on survivorship and symptom trajectories are limited, making this work relatively novel.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Hahn, Theresa E — Roswell Park Cancer Institute Corp
- Study coordinator: Hahn, Theresa E
Related research
Other NIH-funded projects on the same topics.
-
Survivors living with advanced cancer after durable response to immune therapy
This grant follows people who had advanced cancer and responded well to immune checkpoint inhibitors to understand what helps them stay well and how their symptoms change over time.
-
Understanding how some advanced cancer patients benefit long-term from immune therapies
This study is looking at patients with advanced cancer who have had lasting positive results from certain immune treatments, to learn more about what helps them live longer and how to support their needs better.
-
Understanding how survivorship care plans affect health outcomes for cancer survivors
A study will look at whether survivorship care plans help reduce deaths and improve health for adults who have survived cancer.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Meaning-Centered Psychotherapy for Mexican Patients with Advanced Cancer
A cancer center in Mexico will test a culturally adapted therapy to help Mexican patients with advanced cancer find meaning, peace, and purpose at the end of life.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.